{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-280212","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2023-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.205873+00:00","generated_at":"2026-06-07T23:12:47.496853+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Plus Therapeutics Phase 2 GBM trial: mOS 13 mo (63% above SOC), mPFS 11 mo","bullets":["Median overall survival 13 months in 15 rGBM patients, 63% better than SOC bevacizumab (8 mo).","Median progression-free survival 11 months vs SOC 4 months; 9 of 15 patients remain alive.","Delivers up to 20x radiation dose (740 Gy) vs EBRT (35 Gy); favorable safety profile maintained.","Imaging analysis confirms efficacy signal; company to host KOL webinar Nov 20 at 10 am ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-280212","json":"https://secwatch.observer/filing/0001193125-23-280212.json","markdown":"https://secwatch.observer/filing/0001193125-23-280212.md","text":"https://secwatch.observer/filing/0001193125-23-280212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000119312523280212/0001193125-23-280212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000119312523280212/d620464d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T23:12:47.496853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}